Tanvimil D

Dihydrotachysterol

Method of action: Nutritive Agent, Regulating Calcium-Phosphorus Exchange, Replenishing Vitamin D3 Deficiency, Vitamins

Treatment option: Abortion, Amniocentesis, Hypoparathyroidism, Pseudohypoparathyroidism, Crush Injury

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanvimil D

Quick Facts

Property	Description
Active ingredient	Dihydrotachysterol (DHT)
Form	Tablets, Oral Solution
Pharmacological class	Vitamin D Analog / Calcamine
General purpose	Blood Calcium Regulator
Origin	Synthetic Analog (Semi-synthetic)

Identity and Chemical Classification: What Kind of Drug is Tanvimil D?

Tanvimil D is a pharmaceutical preparation defined by its active ingredient, Dihydrotachysterol (DHT), and its primary function as a dedicated blood calcium regulator. The compound Dihydrotachysterol is classified by the World Health Organization (WHO) within the category of Vitamin D and analogues. The drug's identity as a Vitamin D Analog is clinically recognized for its therapeutic efficiency in managing mineral metabolism imbalances. Chemically, the substance is a hydroxy seco-steroid derivative, confirming its specific structure relative to the natural Vitamin D hormonal family.

Composition and Origin: Is Dihydrotachysterol Natural or Synthetic?

Dihydrotachysterol is a synthetic analog produced as a semi-synthetic reduction product of Vitamin D2 (Ergocalciferol). This intentional modification provides key differentiating features from generic supplements. Tanvimil D is consistently supplied as a single product, containing Dihydrotachysterol as the sole active entity. This medication is available for oral administration in dosage forms such as tablets or an oral solution, offering flexibility for different patient groups.

General Purpose: What is the Overall Role of This Medication?

The overall purpose of Tanvimil D is to help the body effectively stabilize and manage its essential calcium and phosphate metabolism. This blood calcium regulator is most typically utilized in scenarios involving hypoparathyroidism, where the body struggles to maintain necessary calcium levels. The unique structure of the DHT molecule is pharmacologically valued because it ensures a reliable action by not requiring the secondary activation step in the kidneys. This distinct mechanism of action provides dependable support for maintaining adequate calcium concentrations in the bloodstream.

What side effects are possible with Tanvimil D?

Possible Side Effects and Safety Information

The safety profile of this multi-component product is primarily defined by the documented risks associated with its constituent vitamins, which typically include high-dose and chronic-use effects of the B-vitamins and fat-soluble vitamins.

Common Adverse Reactions

Adverse effects observed with the components are generally mild and transient, primarily affecting the gastrointestinal system. These may include upset stomach, nausea, abdominal cramps, and diarrhea. Drowsiness, flushing, and temporary discomfort have also been reported with various B-vitamin supplements.

Serious and Clinically Significant Risks

Certain vitamins in high doses or with prolonged use are associated with serious adverse events:

Peripheral Neuropathy: Chronic, high-dose intake of Pyridoxine (Vitamin B6) can lead to severe and potentially permanent peripheral neuropathy, characterized by symptoms like numbness or tingling in the extremities.
Kidney Complications: High doses of Ascorbic Acid (Vitamin C) may increase the risk of forming kidney stones (calcium oxalate calculi), particularly in individuals with pre-existing kidney issues or a history of recurrent stones.
Hypervitaminosis D: Excessive intake of Vitamin D can lead to toxicity, characterized by hypercalcemia (high calcium levels in the blood), which may cause symptoms like vomiting, weakness, frequent urination, and, in severe cases, kidney damage or renal failure.

Safety Considerations and Restrictions

Caution is warranted for specific patient populations. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency face an increased risk of hemolysis (destruction of red blood cells) with high doses of Ascorbic Acid. Patients with iron overload conditions, such as hemochromatosis, should use caution as Vitamin C enhances iron absorption. Furthermore, patients with a history of renal stones or significant kidney impairment require monitoring to mitigate the risk of oxalate nephropathy.

The Tolerable Upper Intake Level (UL) for the individual vitamins must be considered, as long-term intake exceeding these regulatory limits significantly increases the risk of toxicity.

Overdose and Emergency Response

Overdose of Tanvimil D is defined by toxicity resulting from elevated calcium levels in the blood, known as hypercalcaemia. This condition manifests with a cluster of signs and symptoms documented in official regulatory labeling, affecting multiple physiological systems.

Documented Manifestations	Severe Outcomes
Weakness, headache, nausea, vomiting, abdominal cramps, increased thirst (polydipsia), increased urination (polyuria), metallic taste, vertigo, and bone or muscle pain.	Life-threatening hypercalcaemic crisis, renal insufficiency, widespread soft tissue calcification of organs, seizures, coma, and cardiac arrhythmias leading potentially to death.

When to Seek Immediate Medical Help

Immediate medical attention is required for any suspicion of overdose or onset of severe manifestations, especially those indicating a hypercalcaemic crisis. Regulatory guidance mandates the immediate withdrawal of Dihydrotachysterol as the primary emergency action. Treatment in a hospital setting is exclusively symptomatic and supportive. Procedures explicitly described in regulatory sources involve aggressive patient hydration, often utilizing intravenous fluids and loop diuretics to promote calcium excretion. Continuous management of the toxicity requires regular determinations of blood calcium level for control.

Therapeutic Uses of Tanvimil D

Therapeutic Applications of Tanvimil D: Conditions and Benefits

Tanvimil D (Dihydrotachysterol) is commonly used to help manage conditions associated with systemic mineral imbalance. The key therapeutic applications include managing low calcium levels associated with hormonal deficiencies and supporting the management of specific bone disorders. Its therapeutic use plays a role in managing underlying deficiencies and provides supportive relief from associated physical symptoms.

Management of Endocrine-Driven Mineral Deficiencies

This medication is primarily used to help manage conditions involving insufficient parathyroid hormone production, such as Hypoparathyroidism and Pseudohypoparathyroidism, which are marked by clinically low calcium levels (Hypocalcemia). It is commonly applied across chronic and acute presentations, and may assist with stabilizing mineral metabolism and assisting with functional stability.

Managing Symptoms of Heightened Neuromuscular Activity

Tanvimil D is relevant for managing symptom clusters that may become intense or disruptive due to low calcium. It is applied in addressing painful muscle hyperexcitability, including cramps, twitching, and the involuntary contractions known as tetany. This contributes to easing the overall symptom load during acute episodes.

Quick Fact: Relief for Neuromuscular Symptoms
Primary Focus: Applied in addressing symptoms related to heightened physiological activity like cramps and severe tetany.
Patient Benefit: Provides supportive relief when symptoms interfere with routine activities.

Supportive Therapy for Metabolic Bone Diseases

This medication is relevant for managing conditions presenting with systemic or localized discomfort related to bone health, such as Rickets in children and Osteomalacia in adults. It is also used for conditions involving mineral disturbances and bone stress, such as Renal Osteodystrophy, and supports general skeletal well-being and comfort during symptomatic phases.

Eligibility and Restrictions for Use

Tanvimil D contains cholecalciferol (Vitamin D3) and is a supplement used to address or prevent Vitamin D deficiency. While generally safe for most adults, children, and infants when used as directed, certain conditions and other medications can affect its suitability and use.

Contraindications (Should Not Use)

The supplement is contraindicated in individuals with specific pre-existing health conditions due to the risk of exacerbating high calcium and Vitamin D levels in the body. You should not use Tanvimil D if you have:

Hypercalcemia (high levels of calcium in the blood).
Hypervitaminosis D (high levels of Vitamin D in the body).
Hypersensitivity or a known allergic reaction to cholecalciferol, Vitamin D, or any other ingredients in the formulation.

Precautions and Drug Interactions (Consult a Healthcare Professional)

Caution is advised, and consultation with a healthcare professional is necessary for individuals with the following conditions or who are taking certain medications:

Kidney problems (e.g., kidney failure, history of kidney stones).
Granulomatous disorders (e.g., sarcoidosis).
Pregnancy and Breastfeeding.

Certain medications may alter the absorption or metabolism of Vitamin D, potentially requiring a dosage adjustment or closer monitoring. These include:

Medication Type	Examples of Interaction
Thiazide Diuretics	May increase the risk of hypercalcemia.
Anticonvulsants (Phenytoin, Phenobarbital)	May decrease the effectiveness of Vitamin D by speeding up its breakdown.
Cholesterol-lowering agents (Cholestyramine, Orlistat)	May decrease the absorption of Vitamin D.
Cardiac Glycosides (Digoxin)	High Vitamin D doses increase the risk of fatal cardiac arrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tanvimil D (Dihydrotachysterol, DHT) is defined by its role as a blood calcium regulator. Officially documented interactions generally fall into categories that either increase the risk of hypercalcemia or alter the exposure and efficacy of DHT.

Documented Drug–Drug Interactions

Interacting Substance	Officially Described Outcome
Other Vitamin D compounds/analogs	Contraindicated due to additive effects and a heightened risk of severe toxicity and hypercalcemia (abnormally high calcium levels).
Cardiac Glycosides (e.g., Digoxin)	Increased risk of ventricular arrhythmias and digitalis toxicity, a pharmacodynamic outcome linked to elevated serum calcium.
Thiazide Diuretics (e.g., Chlorothiazide)	Increased risk of hypercalcemia due to reduced urinary excretion of calcium.
Anticonvulsants (e.g., Phenytoin, Phenobarbital)	May reduce DHT's therapeutic efficacy via accelerated metabolic breakdown.
Bile Acid Sequestrants (e.g., Cholestyramine)	Decreased serum concentration of DHT due to impaired gastrointestinal absorption.
Corticosteroids	May decrease the therapeutic effectiveness of DHT.

Mechanism of Action

Nuclear Receptor Agonism and Transcriptional Control

The active metabolite of Dihydrotachysterol ( DHT) acts as a direct agonist for the Vitamin D Receptor ( VDR), a nuclear receptor found in target cells across the body. Binding of the molecule initiates a signaling cascade that modulates the transcription of specific genes by influencing Vitamin D Response Elements ( VDREs) on DNA. This molecular action controls the synthesis of proteins required for mineral homeostasis.

Regulation of Mineral Homeostasis

This genomic modulation is applied to the calcium and phosphate homeostasis pathway. The mechanism enhances the creation of calcium-binding proteins in the intestinal epithelium, enhancing the absorption of calcium from the diet. Simultaneously, it promotes the reabsorption of calcium in the kidneys, reducing its excretion. This dual action results in the transfer of calcium ions ( Ca^2+) into the systemic circulation.

PTH-Independent Activation Pathway

A key feature of DHT's mechanism is its structure, which allows it to primarily require only the initial hydroxylation in the liver, effectively bypassing the final, tightly regulated 1alpha-hydroxylation step that occurs in the kidney. By decoupling its activation from this step, the mechanism operates with functional independence from the parathyroid hormone ( PTH) feedback system, thereby contributing to the maintenance of extracellular calcium concentrations.

Dosage and Administration Information

Tanvimil D (Dihydrotachysterol) is administered exclusively via the oral route, available in official dosage forms such as tablets and oral solution or drops. The administration is highly standardized yet requires significant individualization due to the narrow therapeutic range of the drug.

Administration Scope

Feature	Official Instruction Summary
Route of Administration	Oral (by mouth).
Dosing Schedule	Initial: 0.8 mg to 2.4 mg daily for several days. Maintenance: 0.2 mg to 1.0 mg daily. The average is often 0.6 mg daily.
Frequency Pattern	Once daily is the primary frequency. Maintenance may be required daily or on alternate days (liquid form).
Age-Group Rules	Specific pediatric doses are detailed in labeling; for example, infants and children may begin with 1 mg to 5 mg daily for four days, followed by a maintenance dose of 0.5 mg to 1.5 mg daily.

Procedural Conditions for Use

Official instructions mandate specific procedural steps that govern correct use. The dosage must be individualized based on the patient’s response, with adjustments made cautiously at intervals of four to eight weeks after starting the medicine.

Treatment is conditionally dependent on co-administration of oral calcium supplements to ensure adequate intake. Furthermore, use is controlled by regular determinations of blood calcium level (serum calcium), which must be maintained within the specified normal range of approximately 9 to 10 mg/dL. This frequent monitoring is essential during the initial dose titration phase.

Recent Clinical Evidence

Research evidence / Overview of studies for Tanvimil D

Evidence for use in Hypoparathyroidism and Hypocalcemia

Research examined Dihydrotachysterol (Tanvimil D) in the context of blood mineral level maintenance in individuals with Hypoparathyroidism, a condition characterized by functional limitations in regulating calcium. Research has primarily consisted of comparative Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored outcomes related to physical discomfort and systemic or functional imbalance by monitoring serum calcium concentration and the stability of serum phosphate levels. They also examined symptom patterns observed in the populations studied, such as episodes where symptoms become more noticeable, like tetany.

Conventional therapy was observed in trials as the established reference standard for comparison in the assessment of blood level stabilization. Findings describe patterns observed in the studies related to patterns observed when examining chemical stabilization of blood calcium levels. Research provides context, but not individual predictions, regarding the control of calcium levels related to the measurement of calcium levels in this condition.

Evidence for use in Supportive Mineral and Bone Disorders

Dihydrotachysterol was evaluated in research exploring its use as supportive therapy for mineral and bone disorders, including Rickets in children and Osteomalacia in adults, and for conditions associated with physiological strain such as Renal Osteodystrophy. Studies monitoring these chronic conditions consisted of older clinical trials, observational studies, and comparative research examining Dihydrotachysterol against other Vitamin D forms. These studies monitored physiological strain or stress by measuring outcomes related to bone mineralization, and the change in parathyroid hormone (PTH) concentrations.

Evidence Gaps and Areas of Research Uncertainty

The research exploring Tanvimil D has several notable limitations. The certainty of the evidence is affected by the characteristics of the available studies, and many research findings are derived from the broader class of Vitamin D analogs. Long-term effects are not fully established for certain patient-important outcomes, as follow-up durations were limited in many controlled trials. Research highlights what is known—and what is still uncertain—about this conventional treatment approach.

Key Studies & References

World Health Organization Anatomical Therapeutic Chemical (ATC) Classification System: A11CC02 Dihydrotachysterol

Frequently Asked Questions (FAQ)

Common questions about Tanvimil D (FAQ)

Q: How quickly should I expect to feel the effects of Tanvimil D?

According to official product information and research, the onset of action for the active ingredient in Tanvimil D, dihydrotachysterol, typically begins in 4 to 7 days. This indicates that it may take several days for the medication to begin visibly influencing the body's calcium levels.

Q: Is it normal to feel tired when first starting Tanvimil D?

Feeling tired or having weakness are noted as potential early signs of hypercalcemia (abnormally high calcium levels in the blood), which is a possible side effect of the medication. If symptoms like fatigue occur, they may be a sign that blood calcium levels require review.

Q: Is there a generic version of Tanvimil D available?

The active ingredient in Tanvimil D is dihydrotachysterol (DHT). This compound has historically been sold under various brand names. The availability of a specific generic version may vary depending on the local market status of the branded product.

Q: How long does Tanvimil D stay in your system after stopping treatment?

Official information indicates that the time it takes for the effects to cease after withdrawing the drug, known as the offset of action, is generally reported to be 7 to 21 days. During this period, monitoring of calcium levels by a healthcare professional is typically continued.

Q: Can elderly people safely take Tanvimil D?

Clinical studies have included elderly patients, demonstrating the medication's effectiveness in normalizing serum calcium levels. However, careful monitoring of renal function (kidney health) is typically required for all adults, including the elderly, due to risks associated with chronic Vitamin D analog use.

Q: Is Tanvimil D appropriate for use during pregnancy?

Regulatory bodies assign the active ingredient a Pregnancy Category C. This classification indicates that the medication should only be used during pregnancy if the potential benefit to the mother is considered to outweigh the potential risk to the unborn baby.

Q: Can Tanvimil D help with muscle weakness or cramps?

Tanvimil D is indicated to treat conditions like hypocalcemia (low calcium), which can lead to symptoms such as muscle cramps or neuromuscular irritability. If muscle weakness is experienced, it may be a sign of hypercalcemia (toxicity) and should be discussed with a healthcare professional.

Q: What happens if I occasionally forget to take a dose of Tanvimil D?

Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official instructions advise against taking two doses at the same time.

Q: What is the difference between Tanvimil D and just Vitamin D3?

Tanvimil D contains dihydrotachysterol (DHT), which is a synthetic Vitamin D analog. Unlike natural Vitamin D3, DHT has a distinct chemical structure that allows it to effectively bypass a final activation step in the kidneys. This allows it to function with independence from the body's natural parathyroid hormone (PTH) feedback system.

Q: Can I take Tanvimil D if I am breastfeeding?

Official warnings state that the active ingredient in Tanvimil D is excreted in breast milk. This may pose a risk of causing hypercalcemia (high calcium levels) in the nursing infant. Consequently, some regulatory sources indicate that the medication is contraindicated (not recommended) while breastfeeding.

Q: Is it normal for my urine to change color when taking Tanvimil D?

While a direct color change is not commonly noted in regulatory documents, symptoms like polyuria (frequent, large amounts of urination) and nocturia (frequent urination at night) are associated with high serum calcium levels (toxicity). An increase in urination frequency is a symptom that should be discussed with a healthcare professional.

Q: How often do people typically need to get blood tests while taking Tanvimil D?

The treatment with Tanvimil D requires close monitoring. Official instructions mandate that the dosage must be individualized and adjusted based on regular determinations of blood calcium level (serum calcium). These tests are typically essential during the initial dose titration phase and may occur at intervals of four to eight weeks after starting or changing the medicine.

Q: Can Tanvimil D be used in children or adolescents?

Yes, Tanvimil D's active ingredient is used to treat conditions like Rickets in children. Official product labeling provides specific guidance and detailed pediatric doses for infants and children, though its use requires careful, individualized monitoring.

Q: Is a metallic taste in the mouth a possible side effect of Tanvimil D?

Yes, regulatory documents list a metallic taste in the mouth as one of the potential early symptoms of hypercalcemia (Vitamin D toxicity). If this symptom is experienced, it may indicate high calcium levels and should be reported to a healthcare professional.

Q: Can Tanvimil D be taken by people with kidney issues?

Tanvimil D is generally contraindicated in cases of severe hypercalcemia due to Vitamin D toxicity. Caution and close monitoring are required for individuals with kidney problems, such as kidney failure or a history of kidney stones, due to the potential risk of calcium-related complications.

Q: Are there any long-term side effects associated with Tanvimil D use?

Official safety documents warn that long-term complications, particularly with chronic overdosage, can be serious. These can include calcification (calcium deposits) in various tissues, such as the arteries and kidneys, which may potentially lead to conditions like hypertension (high blood pressure) and renal failure (kidney failure).

Q: Can Tanvimil D be used to prevent bone fractures?

Tanvimil D is a blood calcium regulator used to treat underlying bone disorders such as osteomalacia and conditions related to hypoparathyroidism. By treating these conditions and maintaining proper calcium levels, the medication aims to support bone health.

Q: Why do some people need higher doses of Vitamin D, and is Tanvimil D an option for them?

Regulatory documents indicate that the initial dosage of the active ingredient must be individualized based on the patient's specific metabolic response and condition. Tanvimil D, which is available in various dosage forms, is used by healthcare professionals to address the variable needs of patients requiring specialized calcium regulation.

Q: What are the signs that Tanvimil D is working for me?

The success of treatment is primarily measured through the monitoring of your blood calcium level (serum calcium). When the medication is working as intended, your healthcare professional will confirm that your calcium levels are being maintained within the specified normal range of approximately 9 to 10 mg/dL.

Q: What are the most common side effects of taking Tanvimil D?

The safety profile for the multi-component product suggests adverse effects are generally mild and may include upset stomach, nausea, abdominal cramps, and diarrhea. However, the most clinically significant concerns relate to symptoms of hypercalcemia (high calcium) due to the active ingredient, such as weakness or frequent urination.

Q: Can taking Tanvimil D cause stomach upset or nausea?

Yes, upset stomach and nausea are noted as common, generally mild adverse reactions reported with the use of the product's components. If these symptoms become severe or persistent, they should be reviewed by a healthcare professional.

Q: Can I take Tanvimil D with my daily multivitamin?

Official product information contraindicates the use of Tanvimil D with other Vitamin D compounds or analogs due to the high risk of severe toxicity and hypercalcemia. It is important that a healthcare provider reviews the contents of any multivitamin before use alongside Tanvimil D.

Q: Is there a known interaction between Tanvimil D and iron supplements?

The active ingredients in Tanvimil D are known to interact with certain minerals and vitamins. While the official documentation does not specifically list an interaction with iron supplements, patients are generally advised to inform their healthcare professional about all supplements they are taking.

Q: Can I take other herbal supplements while using Tanvimil D?

Official documents detail drug and food interactions but do not specifically address herbal supplements. Because Tanvimil D affects mineral levels, a healthcare provider should be notified about all herbal supplements being taken to check for potential unknown interactions.

Q: Can Tanvimil D interact with other medicines and products?

Yes, Tanvimil D has a notable interaction profile defined by its role as a blood calcium regulator. It can interact with substances that also affect calcium levels, such as Thiazide diuretics and cardiac glycosides. It can also interact with medicines like anticonvulsants which may reduce its efficacy.

Q: Are there any food restrictions while taking Tanvimil D?

Official information advises caution regarding certain dietary intake. Co-administration with a high intake of dietary calcium, phosphate, or other calcium-containing supplements can lead to additive effects, potentially increasing the risk of hypercalcemia (high calcium) or hyperphosphatemia (high phosphate) in the blood.

How should Tanvimil D be stored and disposed of?

How to Store and Dispose of Tanvimil D?

The storage and disposal requirements for Tanvimil D (Dihydrotachysterol) are governed by specific regulatory standards to maintain stability and ensure safety.

Official Storage Requirements

Storage Factor	Requirement (As per Regulatory Labeling)
Temperature & Light	Protect from light; store below 25 C; do not freeze.
Packaging	Keep the product in the original container and ensure the bottle is tightly closed.
Stability Limit	The oral solution must be discarded four months after the first opening; tracking the opening date is required.
Safety	Keep all medicines out of the sight and reach of children (Mandatory).

Official Disposal Instructions

Unused or expired Tanvimil D must be disposed of according to local pharmaceutical waste procedures, usually via an approved waste collection point. It is explicitly prohibited to release the product to the environment or discharge it into sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.